Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

scientific article published on 09 October 2015

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1032129720
P356DOI10.1038/MODPATHOL.2015.98
P698PubMed publication ID26449765

P50authorAndrea Sartore-BianchiQ28321693
Salvatore SienaQ28321703
Giuseppe ToniniQ37838300
Silvio Marco VeroneseQ39051644
Roberto LabiancaQ39950156
Silvia MarsoniQ42882462
Fortunato CiardielloQ43184447
Fotios LoupakisQ46107172
Sara LonardiQ50876272
Vittorina ZagonelQ56925944
Emanuele ValtortaQ57018578
Cosimo MartinoQ61307821
Francesco LeoneQ88197017
Massimo RuggeQ89598250
Patrizia RaccaQ115139909
Katia BencardinoQ117279618
Marcello GambacortaQ117804625
Calogero LauricellaQ117805144
P2093author name stringCarmine Pinto
Giuseppe Aprile
Giuseppe Viale
Mauro Risio
Mauro Truini
Carlo Garufi
Johannes Noe
Stefania Mosconi
Barbara Frau
Claudio Graiff
Frédérique Penaullt-Llorca
Walter Grigioni
P2860cites workComprehensive molecular characterization of human colon and rectal cancerQ24630415
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.Q27824766
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerQ27824847
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialQ27851578
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerQ27851787
Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?Q30856729
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeuticsQ33601653
HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expressionQ33690070
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateQ33862786
Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomasQ34029360
The HER-2/neu oncogene in tumors of the gastrointestinal tractQ34311106
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerQ34344198
HER2/neu testing in primary colorectal carcinomaQ34499615
Significance of human epidermal growth factor receptor 2 expression in colorectal cancerQ34585338
HER2: biology, detection, and clinical implicationsQ35622862
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerQ36678853
Assessment of a HER2 scoring system for gastric cancer: results from a validation studyQ37142266
Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysisQ37251780
Expression of HER2 in colorectal cancer does not correlate with prognosisQ37329191
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.Q38087507
KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.Q39861972
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.Q40291966
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.Q41735415
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingQ42431264
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialQ45217739
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization studyQ47604705
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.Q54402875
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.Q54660628
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateQ57130157
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinomaQ80227762
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring systemQ81299205
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancerQ81711846
Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring systemQ82049151
P433issue11
P921main subjectcolorectal cancerQ188874
colorectal carcinomaQ25493920
P304page(s)1481-1491
P577publication date2015-10-09
P1433published inModern PathologyQ15724578
P1476titleAssessment of a HER2 scoring system for colorectal cancer: results from a validation study
P478volume28

Reverse relations

cites work (P2860)
Q91754859Biomarker-guided therapy for colorectal cancer: strength in complexity
Q38827897Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory
Q54980136Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Q64086039Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis
Q54849840Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.
Q92838804Correlation of HER2 and FOXM1 in human colorectal carcinoma and its clinical significance
Q92256962Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)
Q91830988Current and emerging biomarkers in metastatic colorectal cancer
Q38787244Current and future biomarkers in the treatment of colorectal cancer.
Q39172118Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie
Q39245971Downregulation of ALDOB is associated with poor prognosis of patients with gastric cancer
Q57183898Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Q27853380Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Q90392916Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab
Q37708897HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
Q39120488HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin
Q92885759HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Q28078111HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
Q89868898HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China
Q36671427HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
Q90593024HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
Q59794745Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream
Q50037194Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases
Q58695677Multi-Spectral Fluorescence Imaging of Colon Dysplasia InVivo Using a Multi-Spectral Endoscopy System
Q50089419Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.
Q57739115Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives
Q36432094Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
Q38794338Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications
Q92912017Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal
Q60960810Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases
Q92280751Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Q39223563Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Q64903410Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy.
Q90513170Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
Q40970786Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.
Q39045763Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
Q57162471RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine
Q41105389Recent developments in the treatment of metastatic colorectal cancer.
Q55088555Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
Q91291948Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients
Q30315224Targeting HER2: precision oncology for colorectal cancer
Q54962247Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Q64065309The landscape of d16HER2 splice variant expression across HER2-positive cancers
Q36102672Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Q64262617Update on systemic therapy for colorectal cancer: biologics take sides

Search more.